Carnegie Investment Bank AB (publ) (”Carnegie”) exercises the over-allotment option regarding 4,375,000 B-shares in BioArctic AB (publ) (“BioArctic” or the “Company”). The stabilization period has now ended and no further stabilization transaction will be undertaken in addition to the stabilization transaction performed on the first trading day.
As announced in connection with the offering to acquire newly issued B-shares in the Company and the listing of the Company’s B-shares on Nasdaq Stockholm (the ”Offering”), Carnegie, acting as Global Coordinator, may carry out transactions aimed at supporting the market price of the B-shares at levels above those which might otherwise prevail in the open market.
Stabilization transactions may be undertaken on Nasdaq Stockholm, in the over-the-counter market or otherwise, at any time during the period starting on the date of commencement of trading in the B-shares on Nasdaq Stockholm and ending no later than 30 calendar days thereafter. Carnegie is, however, not required to undertake any stabilization and there is no assurance that stabilization will be undertaken. Stabilization, if undertaken, may be discontinued at any time without prior notice. In no event will transactions be effected at levels above the price in the Offering.
A few existing shareholders have granted Carnegie an over-allotment option to sell up to 4,375,000 additional B-shares, corresponding to up to 15 percent of the total number of B-shares encompassed by the Offering, at a price corresponding to the price in the Offering, i.e. SEK 24, to cover any over-allotment in connection with the Offering. The over-allotment option may be utilized in whole or in part for 30 days from the first date of trading in the Company’s B-shares on Nasdaq Stockholm. Carnegie announces today that the over-allotment option is exercised in full.
Carnegie has, in its capacity as stabilization manager, notified that a stabilization measure has been undertaken on the first trading day, in accordance with article 5(4) in the Market Abuse Regulation 596/2014, on Nasdaq Stockholm as specified below. The contact person at Carnegie is Anna Boqvist (tel: +46 8 588 688 00).
| Stabilization information | |
| Issuer: |
BioArctic AB (publ) |
| Securities: |
B-shares (SE0010323311) |
| Offering size: |
29,166,666 |
| Offer price: |
SEK 24 |
| Ticker: |
BIOA B |
| Stabilization manager: |
Carnegie Investment Bank AB (publ) |
The stabilization period regarding the Offering has now ended and no further stabilization transactions will be effected. Specified below is the summary of the stabilization transaction which has been effected during the stabilization period in accordance with this press release. The transaction during the stabilization period has been effected the first trading day on Nasdaq Stockholm and no stabilization transactions have been effected on other dates than this specified below.
| Stabilization transaction: | ||||||
| Date |
Quantity |
Price (highest) | Price (lowest) | Price (volume weighted average) | Currency | Trading venue |
|
2017-10-12 |
5,700 | 24.00 | 24.00 | 24.00 | SEK |
Nasdaq Stockholm |
This information is information that BioArctic AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact persons below, at 8.00 p.m. CET on November 6, 2017.
For further information, please contact:
Gunilla Osswald, CEO at BioArctic
Email: gunilla.osswald@bioarctic.se
Telephone: + 46 (0)8 695 69 30
Christina Astrén Eriksson, Head of Communications at BioArctic
Email: christina.astren@bioarctic.se
Telephone: + 46 (0)70 835 43 36
Important information
This announcement is not an offer to sell or a solicitation of any offer to buy any securities issued by BioArctic AB.
Copies of this announcement are not being made and may not be distributed or sent into the United States, Australia, Canada, Japan or any other jurisdiction in which such distribution would be unlawful or would require registration or other measures. The securities referred to in this announcement have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), and accordingly may not be offered or sold in the United States absent registration or an exemption from the registration requirements of the Securities Act and in accordance with applicable U.S. state securities laws. The Company does not intend to register any offering in the United States or to conduct a public offering of securities in the United States.
The offering of securities referred to in this announcement has been made by means of a prospectus. This announcement is not a prospectus for the purposes of Directive 2003/71/EC (together with any applicable implementing measures in any Member State, the “Prospectus Directive”). Investors should not invest in any securities referred to in this announcement except on the basis of information contained in the aforementioned prospectus.